Kim, Sang T. http://orcid.org/0000-0003-0926-1840
Chu, Yanshuo
Misoi, Mercy
Suarez-Almazor, Maria E.
Tayar, Jean H.
Lu, Huifang
Buni, Maryam
Kramer, Jordan
Rodriguez, Emma
Hussain, Zulekha
Neelapu, Sattva S. http://orcid.org/0000-0003-1045-4914
Wang, Jennifer
Shah, Amishi Y. http://orcid.org/0000-0002-9007-0621
Tannir, Nizar M.
Campbell, Matthew T. http://orcid.org/0000-0003-1915-4491
Gibbons, Don L. http://orcid.org/0000-0003-2362-3094
Cascone, Tina http://orcid.org/0000-0003-3008-5407
Lu, Charles
Blumenschein, George R.
Altan, Mehmet
Lim, Bora
Valero, Vincente
Loghin, Monica E.
Tu, Janet http://orcid.org/0000-0002-1899-3501
Westin, Shannon N. http://orcid.org/0000-0002-1922-0156
Naing, Aung http://orcid.org/0000-0002-4803-8513
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Abdel-Wahab, Noha
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Hwu, Patrick
Oliva, Isabella C. Glitza
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Patel, Sapna P. http://orcid.org/0000-0003-1339-1517
Zou, Jun http://orcid.org/0000-0002-0112-5118
Futreal, Andrew http://orcid.org/0000-0001-8663-2671
Diab, Adi
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Nurieva, Roza http://orcid.org/0000-0002-8483-1121
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01HL141966, P50CA221703, R01HL143520, K08AR079587)
Article History
Received: 8 April 2021
Accepted: 17 March 2022
First Online: 12 April 2022
Competing interests
: M.S.-A. has served as a consultant for Gilead, Avenue Therapeutics, ChemoCentryx, Pfizer, Eli Lilly and Bristol Myers Squibb. N.A.-W. has received honoraria for serving on a scientific advisory board for ChemoCentryx and served as a consultant for ChemoCentryx. S.S.N. has received personal fees from Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Sellas Life Sciences, Cell Medica/Kuur/Athenex, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics, Bluebird Bio, and Sana Biotechnology; research support from Kite, a Gilead Company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, Acerta, and Adicet Bio; royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy. M.T.C. has received honoraria for serve on a Scientific Advisory Board for Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, served as a consultant for ApricityHealth, Exelixis, Pfizer, non-branded educational programs supported by Bristol Myers Squibb, Exelixis, Merck, Pfizer, Roche, and research funding for clinical trials from ApricityHealth, AstraZeneca, EMD Serono/Pfizer, Exelixis, and Janssen. D.L.G. declares advisory board work for Janssen, AstraZeneca, GlaxoSmithKline and Sanofi. D.L.G. receives research grant funding from AstraZeneca, Janssen, Astellas, Ribon Therapeutics, NGM Therapeutics and Takeda. M.A. declares advisory board work for GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca. M.A. has received speaker fees from AstraZeneca, and Nektar Therapeutics. M.A. received research funding from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, and Shattuck Lab. S.N.W. received research grants to the institution from AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Cotinga Pharmaceuticals, Bayer, Bio-Path, and ArQule, and received consulting fees from AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Merck, Pfizer, Eisai, Zentalis, Circulogene, and Agenus. A.N. received research grants to the institution from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol- Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG. M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothyreon. T.C. has received speakers’ fees from the Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape Oncology and PeerView Institute for Medical Education; reports consulting/advisory role fees from MedImmune, AstraZeneca, Bristol Myers Squibb, Merck & Co., Genentech, Arrowhead Pharmaceuticals and EMD Serono; reports institutional clinical research funding from Boehringer Ingelheim, MedImmune, AstraZeneca, EMD Serono, and Bristol Myers Squibb. The remaining authors declare no competing interests.